CD8A and neoplasm: Consequently, SMC18 significantly enhances macrophage phagocytosis of tumor cells, increases infiltration and restores the activity of CD8+ T cells in the tumor microenvironment, exhibits robust anti-tumor effects by inhibiting tumor growth with minimal side effects both in vitro and in vivo.